Ignet

Gene Information

Gene symbol: TBPL2

Gene name: TATA box binding protein like 2

HGNC ID: 19841

Synonyms: TRF3, TBP2

Related Genes

#	Gene Symbol	Number of hits
1	IFNG	1 hits
2	INS	1 hits
3	MAP3K5	1 hits
4	TXN	1 hits
5	TXNIP	1 hits
6	UCP2	1 hits

Related Sentences

#	PMID	Sentence
1	16685406	Expression of thioredoxin and thioredoxin-binding protein-2 in the liver of patients with chronic hepatitis C as a predictor of response to interferon therapy.
2	16685406	The aim of this study was to evaluate the clinical significance of the expression of TRX and thioredoxin-binding protein-2 (TBP-2), which is a negative regulator of TRX function, in the liver of patients with chronic hepatitis C and the relationship of this to the efficacy of interferon (IFN) treatment.
3	16685406	TRX and TBP-2 mRNA levels in the liver biopsy specimens were amplified by real-time RT-PCR.
4	16685406	TRX and TBP-2 levels in the liver tended to decrease slightly with increased fibrosis stage, although not significantly.
5	16685406	TBP-2 mRNA levels in the liver were significantly higher in responders than non-responders to the IFN therapy (p<0.05).
6	16685406	TRX and TBP-2 mRNA levels in the liver before IFN therapy may predict the outcome of IFN therapy in patients with chronic serotype 1 HCV infection.
7	16685406	Expression of thioredoxin and thioredoxin-binding protein-2 in the liver of patients with chronic hepatitis C as a predictor of response to interferon therapy.
8	16685406	The aim of this study was to evaluate the clinical significance of the expression of TRX and thioredoxin-binding protein-2 (TBP-2), which is a negative regulator of TRX function, in the liver of patients with chronic hepatitis C and the relationship of this to the efficacy of interferon (IFN) treatment.
9	16685406	TRX and TBP-2 mRNA levels in the liver biopsy specimens were amplified by real-time RT-PCR.
10	16685406	TRX and TBP-2 levels in the liver tended to decrease slightly with increased fibrosis stage, although not significantly.
11	16685406	TBP-2 mRNA levels in the liver were significantly higher in responders than non-responders to the IFN therapy (p<0.05).
12	16685406	TRX and TBP-2 mRNA levels in the liver before IFN therapy may predict the outcome of IFN therapy in patients with chronic serotype 1 HCV infection.
13	16685406	Expression of thioredoxin and thioredoxin-binding protein-2 in the liver of patients with chronic hepatitis C as a predictor of response to interferon therapy.
14	16685406	The aim of this study was to evaluate the clinical significance of the expression of TRX and thioredoxin-binding protein-2 (TBP-2), which is a negative regulator of TRX function, in the liver of patients with chronic hepatitis C and the relationship of this to the efficacy of interferon (IFN) treatment.
15	16685406	TRX and TBP-2 mRNA levels in the liver biopsy specimens were amplified by real-time RT-PCR.
16	16685406	TRX and TBP-2 levels in the liver tended to decrease slightly with increased fibrosis stage, although not significantly.
17	16685406	TBP-2 mRNA levels in the liver were significantly higher in responders than non-responders to the IFN therapy (p<0.05).
18	16685406	TRX and TBP-2 mRNA levels in the liver before IFN therapy may predict the outcome of IFN therapy in patients with chronic serotype 1 HCV infection.
19	16685406	Expression of thioredoxin and thioredoxin-binding protein-2 in the liver of patients with chronic hepatitis C as a predictor of response to interferon therapy.
20	16685406	The aim of this study was to evaluate the clinical significance of the expression of TRX and thioredoxin-binding protein-2 (TBP-2), which is a negative regulator of TRX function, in the liver of patients with chronic hepatitis C and the relationship of this to the efficacy of interferon (IFN) treatment.
21	16685406	TRX and TBP-2 mRNA levels in the liver biopsy specimens were amplified by real-time RT-PCR.
22	16685406	TRX and TBP-2 levels in the liver tended to decrease slightly with increased fibrosis stage, although not significantly.
23	16685406	TBP-2 mRNA levels in the liver were significantly higher in responders than non-responders to the IFN therapy (p<0.05).
24	16685406	TRX and TBP-2 mRNA levels in the liver before IFN therapy may predict the outcome of IFN therapy in patients with chronic serotype 1 HCV infection.
25	16685406	Expression of thioredoxin and thioredoxin-binding protein-2 in the liver of patients with chronic hepatitis C as a predictor of response to interferon therapy.
26	16685406	The aim of this study was to evaluate the clinical significance of the expression of TRX and thioredoxin-binding protein-2 (TBP-2), which is a negative regulator of TRX function, in the liver of patients with chronic hepatitis C and the relationship of this to the efficacy of interferon (IFN) treatment.
27	16685406	TRX and TBP-2 mRNA levels in the liver biopsy specimens were amplified by real-time RT-PCR.
28	16685406	TRX and TBP-2 levels in the liver tended to decrease slightly with increased fibrosis stage, although not significantly.
29	16685406	TBP-2 mRNA levels in the liver were significantly higher in responders than non-responders to the IFN therapy (p<0.05).
30	16685406	TRX and TBP-2 mRNA levels in the liver before IFN therapy may predict the outcome of IFN therapy in patients with chronic serotype 1 HCV infection.
31	17115886	Thioredoxin and glutaredoxin systems in mammalian cells utilize thiol and selenol groups to maintain a reducing intracellular redox state acting as antioxidants and reducing agents in redox signaling with oxidizing reactive oxygen species.
32	17115886	The role of thioredoxin and glutaredoxin in antioxidant defense and the role of thioredoxin in controlling recruitment of inflammatory cells offer potential use in clinical therapy.
33	17115886	Thioredoxin and binding proteins (ASK1 and TBP2) appear to control apoptosis or metabolic states such as carbohydrate and lipid metabolism related to diseases such as diabetes and atherosclerosis.
34	21119640	Disruption of TBP-2 ameliorates insulin sensitivity and secretion without affecting obesity.
35	21119640	In this study, we show that disruption of thioredoxin binding protein-2 (TBP-2, also called Txnip) in obese mice (ob/ob) dramatically improves hyperglycaemia and glucose intolerance, without affecting obesity or adipocytokine concentrations.
36	21119640	TBP-2-deficient ob/ob mice exhibited enhanced insulin sensitivity with activated insulin receptor substrate-1/Akt signalling in skeletal muscle and GSIS in islets compared with ob/ob mice.
37	21119640	The elevation of uncoupling protein-2 (UCP-2) expression in ob/ob islets was downregulated by TBP-2 deficiency.
38	21119640	In β-cells, TBP-2 enhanced the expression level and transcriptional activity of UCP-2 by recruitment of peroxisome proliferator-activated receptor-γ co-activator-1α to the UCP-2 promoter.
39	21119640	Thus, TBP-2 is a key regulatory molecule of both insulin sensitivity and GSIS in diabetes, raising the possibility that inhibition of TBP-2 may be a novel therapeutic approach for T2DM.
40	21119640	Disruption of TBP-2 ameliorates insulin sensitivity and secretion without affecting obesity.
41	21119640	In this study, we show that disruption of thioredoxin binding protein-2 (TBP-2, also called Txnip) in obese mice (ob/ob) dramatically improves hyperglycaemia and glucose intolerance, without affecting obesity or adipocytokine concentrations.
42	21119640	TBP-2-deficient ob/ob mice exhibited enhanced insulin sensitivity with activated insulin receptor substrate-1/Akt signalling in skeletal muscle and GSIS in islets compared with ob/ob mice.
43	21119640	The elevation of uncoupling protein-2 (UCP-2) expression in ob/ob islets was downregulated by TBP-2 deficiency.
44	21119640	In β-cells, TBP-2 enhanced the expression level and transcriptional activity of UCP-2 by recruitment of peroxisome proliferator-activated receptor-γ co-activator-1α to the UCP-2 promoter.
45	21119640	Thus, TBP-2 is a key regulatory molecule of both insulin sensitivity and GSIS in diabetes, raising the possibility that inhibition of TBP-2 may be a novel therapeutic approach for T2DM.
46	21119640	Disruption of TBP-2 ameliorates insulin sensitivity and secretion without affecting obesity.
47	21119640	In this study, we show that disruption of thioredoxin binding protein-2 (TBP-2, also called Txnip) in obese mice (ob/ob) dramatically improves hyperglycaemia and glucose intolerance, without affecting obesity or adipocytokine concentrations.
48	21119640	TBP-2-deficient ob/ob mice exhibited enhanced insulin sensitivity with activated insulin receptor substrate-1/Akt signalling in skeletal muscle and GSIS in islets compared with ob/ob mice.
49	21119640	The elevation of uncoupling protein-2 (UCP-2) expression in ob/ob islets was downregulated by TBP-2 deficiency.
50	21119640	In β-cells, TBP-2 enhanced the expression level and transcriptional activity of UCP-2 by recruitment of peroxisome proliferator-activated receptor-γ co-activator-1α to the UCP-2 promoter.
51	21119640	Thus, TBP-2 is a key regulatory molecule of both insulin sensitivity and GSIS in diabetes, raising the possibility that inhibition of TBP-2 may be a novel therapeutic approach for T2DM.
52	21119640	Disruption of TBP-2 ameliorates insulin sensitivity and secretion without affecting obesity.
53	21119640	In this study, we show that disruption of thioredoxin binding protein-2 (TBP-2, also called Txnip) in obese mice (ob/ob) dramatically improves hyperglycaemia and glucose intolerance, without affecting obesity or adipocytokine concentrations.
54	21119640	TBP-2-deficient ob/ob mice exhibited enhanced insulin sensitivity with activated insulin receptor substrate-1/Akt signalling in skeletal muscle and GSIS in islets compared with ob/ob mice.
55	21119640	The elevation of uncoupling protein-2 (UCP-2) expression in ob/ob islets was downregulated by TBP-2 deficiency.
56	21119640	In β-cells, TBP-2 enhanced the expression level and transcriptional activity of UCP-2 by recruitment of peroxisome proliferator-activated receptor-γ co-activator-1α to the UCP-2 promoter.
57	21119640	Thus, TBP-2 is a key regulatory molecule of both insulin sensitivity and GSIS in diabetes, raising the possibility that inhibition of TBP-2 may be a novel therapeutic approach for T2DM.
58	21119640	Disruption of TBP-2 ameliorates insulin sensitivity and secretion without affecting obesity.
59	21119640	In this study, we show that disruption of thioredoxin binding protein-2 (TBP-2, also called Txnip) in obese mice (ob/ob) dramatically improves hyperglycaemia and glucose intolerance, without affecting obesity or adipocytokine concentrations.
60	21119640	TBP-2-deficient ob/ob mice exhibited enhanced insulin sensitivity with activated insulin receptor substrate-1/Akt signalling in skeletal muscle and GSIS in islets compared with ob/ob mice.
61	21119640	The elevation of uncoupling protein-2 (UCP-2) expression in ob/ob islets was downregulated by TBP-2 deficiency.
62	21119640	In β-cells, TBP-2 enhanced the expression level and transcriptional activity of UCP-2 by recruitment of peroxisome proliferator-activated receptor-γ co-activator-1α to the UCP-2 promoter.
63	21119640	Thus, TBP-2 is a key regulatory molecule of both insulin sensitivity and GSIS in diabetes, raising the possibility that inhibition of TBP-2 may be a novel therapeutic approach for T2DM.